Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,249.16 -28.35 (-0.54%) Dow
38,299.71 -386.61 (-1.00%) Nasdaq
16,711.39 -23.62 (-0.14%) Bitcoin USD
69,223.47 +1,176.77 (+1.73%) CMC Crypto 200
1,485.76 +17.83 (+1.21%)
PFE Mar 2025 22.500 put
| Previous close | 0.6000 |
| Open | 0.4900 |
| Bid | 0.4200 |
| Ask | 0.7000 |
| Strike | 22.50 |
| Expiry date | 2025-03-21 |
| Day's range | 0.4600 - 0.4900 |
| Contract range | N/A |
| Volume | |
| Open interest | 29.11k |
Business WirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, June 03, 2024--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 11:20 a.m. Eastern Daylight Time.
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
Business WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NEW YORK, June 01, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0
